Comparatively to conventional chemoradiotherapy, a phase 3 trial suggests that platinum-based chemotherapy, radiotherapy, and durvalumab (an immune checkpoint inhibitor of PD-L1) as combinational therapy for lung cancer offer greater benefits, potentially extending overall survival (up to 4 years) in patients with stage III NSCLC [50]. This evidence concerns the gene CD274 and lung cancer.